Archive for the ‘Consumerism’ Category
CLEAR Announces New Policy On Home Cultivation Of Cannabis
In the past, CLEAR has refused to carry advertising or information from seed banks. The view we have taken is that although seeds are perfectly legal until germinated, promoting them is precious close to incitement to break the law and the position that we have maintained is to promote reform of the law.
Our position on this has changed.
Typical small grow tent 60cm x 60cm
Cannabis for medical use is no longer a matter for the criminal law. However, the absurd NHS guidelines are preventing doctors from prescribing freely. The entire purpose of the reforms is being subverted by ignorance. The doctors responsible for the guidance are preferring their own cowardice, reluctance to learn and the comfort of established prejudice rather than patients’ best interests.
People who need cannabis as medicine, unless they are fortunate enough to have one of the very few well informed doctors, have only two choices – go private, where doctors will typically make more independent decisions, or continue to source their medicine from the criminal market.
In these circumstances the ethical and economic choice is to grow your own.
With modern equipment, for an investment of just £200 – £300, one or two autoflowering plants can be grown in a purpose-designed tent with a modest power lamp, perhaps 250 watts, and odour filtration. It takes only a little practice to produce a reliable harvest of 100 – 150 grams of high quality bud every three months, sufficient for most personal needs.
Although technically this remains a criminal offence, provided you are discreet and respectful of others, there is very little chance of detection and there is hardly any enforcement going on anyway. The police don’t have the time and resources to deal with violent crime and burglaries, let alone someone growing for peronsal use only. If you have a medical condition for which there is evidence cannabis can help, the chances of being prosecuted for one or two plants are very small.
Cannabis Professionals. The Trade Association for the UK’s Cannabis, CBD and Hemp Businesses
Cannabis Professionals (CannaPro) is the trade association for the UK’s cannabis, CBD and hemp businesses.
CannaPro will represent this fast-growing sector to the authorities, standing up to the Home Office, MHRA, FSA and Trading Standards, advocating for members’ interests, not acting as a government enforcer but as our members’ champion and to promote the development of the legal cannabis sector.
CannaPro will offer guidance and support to all businesses, helping them to navigate through law and regulations on drugs, medicines, food and cosmetics.
CannaPro will also launch a social media campaign, aiming to inform and educate the public about the benefits of CBD and the pitfalls. The market is full of scammers, fake claims and snake oil salesmen. Because of the historic stigma and fear around cannabis, government authorities are doing nothing, many people are misinformed and misunderstand. CannaPro will explain the facts clearly and direct consumers to certified businesses which they can rely on.
Membership of CannaPro is without charge. All guidance will be published openly for everyone to benefit from. Free-of-charge support and answers to individual questions will be available online.
Businesses wishing to be certified by CannaPro will be reviewed for their products, trading standards, marketing and conduct. Certified companies will be entitled to display the CannaPro badge as a mark of quality, ethics and reliability.
Backed by CLEAR, the UK’s longest-established cannabis group with a network exceeding all other UK drugs policy groups combined, CannaPro members will benefit from CLEAR’s wide reach and influence with UK consumers.
Website: https://cannapro-uk.org
Facebook Group: https://www.facebook.com/groups/cannapro/
What Is The Matter With Doctors About The Use Of Cannabis As Medicine?
In the UK, most doctors, and the medical profession as a whole, are ignorant and bigoted about cannabis.
Their ignorance is not entirely their own fault. For 50-odd years, since cannabis tincture was last available from UK pharmacies, they have been subject to the same relentless tide of propaganda from the Home Office, successive governments, the tabloid press and rabble-rousing politicians as the rest of society. Many still regard cannabis as a dangerous drug consumed by degenerates that almost inevitably leads to mental illness. The idea that it could be a safe and effective medicine which offers real benefits in a wide range of conditions is regarded as laughable.
However, there is no excuse for such laziness amongst a profession that regards itself as scientific. And this is the charge – indolence, carelessness and laziness – that needs to be laid at those doctors at NHS England, the Royal College of Physicians and the British Paediatric Neurologists Association, that are responsible for the disgraceful ‘guidelines’ published two weeks ago.
Throughout Europe, Israel, Canada and the USA there are thousands of doctors who have made the effort to learn about cannabinoid medicine. They have had to make extraordinary effort to do because even the most basic science is still rarely taught. The endocannabinoid system is on the syllabus of very few medical schools, anywhere in the world, despite the fact we now know that it is the largest neurotransmitter network in the body and affects almost every aspect of our health and all medical conditions. This is a dreadful indictment of the medical establishment but particularly of doctors in the UK, very few of whom have made any effort at all.
So while, to a degree, the ignorance can be forgiven, the bigotry cannot. It is cowardice. These doctors prefer to cover their own backs, protect themselves and prefer an absurd level of caution to doing what is in their patients’ best interests. The incredibly low risk attached to cannabis in any form, at any age and particularly when under medical supervision, is simply overlooked.
Yes, the medical profession is known to be ‘conservative’ but in the case of cannabis this is an excuse. Yes, we live in an increasingly litigious society but any truly professional doctor would not be cowed by such fear when the evidence is widely available, if they could be bothered to look. And what is this ‘conservatism’ of? Modern medicine is barely a century old. It is new in the history of our species and while the reductionist approach has brought great benefit and made huge advances, it is at the expense of thousands of years of human experience which has been dismissed as valueless.
These doctors may feel that the reforms have been foisted on them with no consultation and little notice but this is not a political game, it affects the lives of millions, from the youngest baby to the oldest, most senior citizens. These doctors are failing in their professional duty. For too long they have enjoyed being regarded with ultimate respect, rarely being questioned or challenged by their patients but those days are gone. Most of the population is now far better informed than ever before, largely because of the internet and although this may cause doctors some problems, they have to learn to live with it. They have to respect their patients, parents and carers and recognise more than ever before that healthcare is about co-operation, about working together. They have to come down from their ivory towers and start delivering truly patient-centred medicine.
NHS Guidelines Offer People Who Need Cannabis As Medicine Two Choices. Go Private Or Carry On Being A Criminal.
Go Private…
…Or Be A Criminal
Following the new Misuse of Drugs Regulations, which came into force on 1st November, the NHS has issued guidelines on cannabis for medical use, both for clinicians and for the public.
The best that can be said about these is that they are NOT the law. In fact they are inaccurate, misleading and provide a seriously distorted picture both of the new regulations and of the evidence that is available on the use of cannabis as medicine. The crucial points are these. There are NO RESTRICTIONS on what conditions cannabis may be prescribed for. As well as oils, raw herbal cannabis may also be prescribed – for vaping only, smoking is prohibited. All the decisions are entirely in the hands of the prescribing consultant.
Of course, the problem is your consultant likely knows nothing about cannabis.
Action is being taken on medical education but it is going to take time. On the authority of the prescribing NHS consultant depends the funding to acquire whatever form of cannabis is required, in itself a difficult process as export licences will have to be obtained in the country of origin, either the Netherlands or Canada. So for those that can afford it, going to a private clinic could be the quickest and most efficient way of getting the medicine that they need. In fact, it’s becoming increasingly clear, it may be the only way.
For most people, already using cannabis as medicine, this means they will carry on as before, either growing themselves, sourcing supply from friends, acquaintances or dealing with the criminal market, dealers who cannot be trusted, product of unknown quality.
My advice? In the present circumstances, I really believe the state no longer has any moral authority to prosecute anyone who can show they are using cannabis for medicine. As the state has now recognised ‘conclusive evidence’ of medicinal benefit, the position has changed since the infamous R v Quayle case of 2005. I believe the Court would now support medical necessity as an argument.
So I advise you to grow. If you are able and have the space, it is the best option. For an investment of a few hundred pounds, purchase a fully configured set up of tent, light, irrigation and ventilation. Grow autoflowering seeds, just one or two plants at a time will meet most individual needs. With modern equipment, it really is much easier and more reliable than you might think.
This is a radical change in my advice and in CLEAR policy but as explained it is now fully justified.
But for those that can afford it, there is now a huge unmet need that surely private operators will step in to fulfil? It is a huge opportunity. It’s now perfectly legal to establish a private cannabinoid medicine clinic. This will represent the cutting edge of the new medical cannabis market. It will require highly specialised doctors who are on the GMC’s specialist register. With a few months intensive training in Canada or the USA, possibly the Netherlands, an admin team that gets efficient with the procedures necessary to import. This is the makings of a very exciting, profitable new, private medicine enterprise, charging very expensive fees.
I understand this will offend some but I believe it must be encouraged. This is what will push the NHS to catch up. Historically, advances in medicine have always happened in the private sector first. This is how cannabis medicine has prospered in other countries and it will be the same in the UK.
So, the problem is still far from solved. For some years, many people will continue to suffer unnecessarily but we have made huge strides and the war is won. Now we must make the peace.
CLEAR Advises Department of Health and MHRA on Definition of Cannabis-Derived Medicinal Products.
Last week, CLEAR was invited to participate in a teleconference with representatives of the Department of Health and Social Care (DHSC) and the Medicines and Healthcare products Regulatory Agency (MHRA). This followed our written submissions made over the last few weeks.
The teleconference included two representatives from each party. The DHSC was represented by the Medicines Pharmacy and Industry section. The MHRA was represented by the Licensing Division.
CLEAR has now submitted a summary of all the advice offered which is reproduced below.
1. The definition of cannabis-derived medicinal products (CDMP) is for products that will be re-scheduled in the Misuse of Drugs Regulations out of schedule 1 and ostensibly into schedule 2. These products will be available for prescription by doctors.
2. With the exception of Sativex, a whole plant cannabis extract with a THC:CBD ratio of 1:1, there are no cannabis-derived medicinal products available in the UK which have been licensed by the granting of a marketing authorisation (MA) or a Traditional Herbal Registration (THR). THR licensing is for minor ailments only that do not require the supervision of a doctor. MA licensing would be required for any CDMP aiming to treat most of the conditions for which cannabis is currently being used illicitly unless such CDMPs are prescribed as an unlicensed medicine.
3. In every other jurisdiction in the world where CDMPs are legally available, governments have recognised that licensing regimes designed to regulate single molecule pharmaceutical medicines synthesised in a lab are not suitable for regulating CDMPs. All such governments have either established entirely new cannabis regulators or created a specialist division within the existing medicines regulator. If there is a genuine intent to enable legal access to CDMPs by the estimated one million people currently using illicit cannabis as medicine, this is the only practical route forwards. The cost and length of time involved in obtaining an MA makes them prohibitive for a plant-based medicine. Given the experience of using cannabis as medicine over many millennia, its non-toxic nature and very low risk profile, the rigorous approach of an MA is unnecessary.
Recommendation 1. A CDMP regulator should be established encompassing genuine expertise in the use of cannabis as medicine. The Cannabis Trades Association UK (CTA) is already in the process of developing the Cannabis Products Directive (CPD) in co-operation with the MHRA and FSA.
4. There is no justification or evidence that can support cannabis being in such a restrictive schedule as schedule 2 alongside opioids and cocaine. The potential for causing social harm, which is the criterion used to determine the correct schedule, is several orders of magnitude greater with all existing schedule 2 drugs. They are all demonstrated to produce far higher levels of problematic dependence and long-term health harms than cannabis.
Recommendation 2. CDMPs should be re-scheduled into schedule 4 alongside Sativex.
5. The primary objective of the definition should be to ensure that the products are safe. Cannabis is non-toxic with no practical lethal dose and any harmful health or social effects are only likely with sustained and abusive use. In normal, moderate and especially medical use the potential for any harm is extremely low, certainly no higher than with common over-the-counter medicines. The main safety considerations are therefore the risk of contamination during cultivation and in subsequent processes such as extraction and refinement of oils, arising from the use of pesticides, herbicides, nutrients and solvents.
6. The definition should be wide enough to encompass all cannabis products that are produced to specified quality standards. It should not be so narrow as to prohibit high THC and/or low CBD products that may well be appropriate in individual circumstances. Prescribing guidelines should be issued to enable doctors to make appropriate clinical judgements on appropriate THC:CBD ratios for different conditions. These guidelines must be compiled by experts in the use of cannabis as medicine, not by the ‘non-experts’ who have been appointed to the expert panel on cannabis-derived medicine. FOI Requests have revealed that none of the members of the panel have any knowledge, experience or expertise in the use of cannabis as medicine.
7. The definition should be wide enough to provide for a future in which doctors can vary THC:CBD ratios and terpene content in accordance with evidence for therapeutic effect. For example, in paediatric epilepsy, CBD has been shown to be the most important compound but some children require a small percentage of THC for it to become effective. Doctors should be free to vary dosage in the same way as they do with many licensed medicines in accordance with the way the patient responds.
8. Regulators/authorities will properly require some independent assessment of the safety of products as defined above. The only such assessments currently available are Good Manufacturing Practice (GMP) and certification by the Cannabis Trades Association UK (CTA). By definition, these certifications are only available for products that are legally available and CTA only operates within the UK where only exempt, low-THC products (known as CBD products) are legally available. GMP certification is available on some cannabis products legally available outside the UK.
9. Cannabis consists of around 500 molecules including approx. 110 cannabinoids, 120 terpenes and 20 flavonoids which provide the important therapeutic effects, most effectively, when working together in what is known as ‘the entourage effect’. The most significant cannabinoids are believed to be THC and CBD. THC has long been demonised as the principal psychoactive component but it has very important therapeutic effects, notably as an analgesic, an anti-spasmodic and an appetite stimulant. CBD works as an analgesic, anti-inflammatory, anxiolytic and anti-psychotic. It is beyond doubt that they work best together as they enhance each other’s positive effects and ameliorate any side effects. It is vital that cannabis for medical use contains a balance of both. In some conditions, THC is more important than CBD and in others the reverse will be the case. We recommend that for medical use the ratio of THC:CBD should ideally not be less than 10:1. This will protect against any negative effects of THC which a very small proportion of patients may be vulnerable to. In most instances, for medical use, the ideal THC:CBD ratio will be 1:1. Doctors should however be free to prescribe outside these parameters including high THC and high CBD products, subject to prescribing guidelines.
Recommendation 3. The definition of CDMPs should be primarily concerned with safety in the production process. CDMPs should have either a. GMP certification b. CTA certification c. an existing MA d. an existing THR. The composition and cannabinoid ratios of CDMPs should be a matter for determination by doctors in accordance with prescribing guidelines.
Recommendation 4. Prescribing guidelines for CDMPs should be developed by experts in the use of cannabis as medicine, not by the ‘non-experts’ who have been appointed to the expert panel on cannabis-derived medicine.
10. Cannabis has traditionally been smoked and millions of people have gained great benefit from it over many centuries. The principal benefits of smoking, which are extremely important, without any of the negative effects, can now be achieved through vaporising. The benefits are rapid onset of therapeutic effect and accurate self-titration of dose. When ingested, either through the GI system or absorbed through the mucus membranes, onset is much slower, the effect is prolonged and accurate titration is very difficult to achieve. Vaporisers are already in widespread use and a variety of different types are available. The Storz and Bickel ‘Volcano’ has a CE mark and is a licensed medical device in Canada and Israel. The Teva Pharma ‘Syqe’ has completed three clinical trials with positive outcomes for safety and efficacy.
11. Vaporised, pharmaceutical-quality, standardised herbal cannabis with consistent cannabinoid and terpene levels is the gold standard in the use of cannabis as medicine. Presently the only way to achieve this in Europe is with GMP-certified cannabis produced by Bedrocan BV, the Netherlands government officially contracted producer. Some Canadian producers are also GMP certified.
Recommendation 5. Vaporisers should be made available on loan, for subsidised purchase or free-of-charge in accordance with existing provision for those in receipt of benefits.
12. The DHSC should prevail on GW Pharmaceuticals to reconsider its pricing strategy on Sativex which is presently under a ‘do not prescribe’ edict from NICE on the grounds that it is not cost-effective. The price of Sativex is extraordinarily high and products which, for all practical considerations of safety and efficacy, are identical are available over-the-counter for one-tenth of the price in US cannabis dispensaries. There is no justification for the price of Sativex except for the recovery of the cost of clinical trials which GW Pharma was required to engage in in order to obtain a marketing authorisation. GW Pharmaceuticals should also be encouraged to make herbal cannabis products available as an alternative to Bedrocan, something it should be able to achieve within a few months with little difficulty.
13. Cannabis extracts and oils will be required for some patients, particularly children, and those that cannot or do not wish to use inhalation via a vaporiser. Prescribing guidelines must recognise that the pharmacology of cannabis is totally different when ingested through the GI system or absorbed through the mucus membranes. Absorption of oil through suppositories has also been found to a valuable method of ingestion.
14. While CLEAR fully supports decriminalisation of domestic cultivation of cannabis for personal use, homegrown cannabis should never be considered part of a therapeutic programme under the supervision of medical professionals. The potential for contamination and poor quality is far too high.
Recommendation 6. In the short term, aside from low-THC exempt products known as CBD products, the only CDMPs readily available are from GW Pharmaceuticals, Bedrocan BV or Canadian producers, notably Tilray. Standardised herbal cannabis for vaporising or oils for other methods of ingestion should be available from these producers immediately.
15. Originally Nick Hurd MP, the Home Office minister, wrote in The Times, 29th June 2018, that cannabis would be rescheduled and could be prescribed by GPs whenever a benefit could be identified. Without any explanation that now appears to have morphed into ‘specialist’ or ‘senior’ clinicians and only in cases of ‘exceptional clinical need’. As well as a broken promise which is causing widespread consternation, this is irrational, as are suggestions that cannabis should be regarded as a medicine of last resort. The safety profile of cannabis is such that any rational, evidence-based policy would suggest cannabis as a medicine well before many analgesics, anxiolytics and anti-depressants which are widely, readily and regularly prescribed by doctors without any concern.
16. A workable definition of CDMPs together with well-informed prescribing guidelines that enable prescription by GPs for any condition where a benefit is identified is essential. Unless this is satisfactorily achieved, the one million people in the UK currently using cannabis as medicine will continue to do outside the law, outside any form of medicines regulation and without any medical supervision. The likelihood is that this cohort of patients will continue to expand rapidly as knowledge of the therapeutic benefits of cannabis and its use in other countries becomes more widespread. The implications of failing to establish a proper regime are very significant for health, patient-doctor relationships, the criminal market in cannabis, the police and the criminal justice system. This is a nettle that must be grasped.
Recommendation 7. CDMPs should be available in accordance with the Home Office’s initial commitment, that is on prescription by GPs for any condition where a benefit can be identified
Sainsbury’s Now Stocking Legal Cannabis Products As UK Policy Looks Increasingly Shambolic.
In another demonstration of how fast attitudes are changing, Love Hemp water containing soluble CBD cannabis extract is now on sale in a number of Sainsbury’s stores.
This is a remarkable achievement by the team at Love Hemp who are remaining tight lipped about the terms of the deal. A store manager told me that the product is on test in about 100 stores.
Cannabis prohibition is crumbling and the Home Office seems increasingly our of touch with reality with its futile attempts to enforce a policy which nobody is taking any notice of. The real effect of the medical reforms should become clear within the next few weeks. The expert panel process has been revealed as little more than a farce. We still have an outstanding FOI Request on the issue but interim responses seem to confirm that not a single member of the panel, so-called ‘experts’ has any knowledge, experience or expertise in the use of cannabis as medicine.
We await the definition of a cannabis-based product which will determine which products will be re-scheduled and also a decision on who may prescribe. Initial overtures from the MHRA to both CLEAR and the CTA to consult on these issues have come to nothing. It seems that little if anything has been achieved over the summer break.
Home Office licensing policy is also looking increasingly ridiculous. It is refusing any licence application for low THC cultivation where any mention of CBD is made, while every other EU country is striding ahead and British CBD suppliers are having to import all their oil, which they do without any difficulty uner EU free movement rules.
A twist which reveals the absurdity of Home Office policy is that Love Hemp water, which is entirely THC free, is not the first cannabis product that Sainsbury’s has stocked. For many years it has been stocking Good Hemp hempseed oil. Recent lab tests have revealed that THC levels in Good Hemp oil exceed the 1mg limit in each bottle, meaning that it cannot be regarded as exempt under the Misuse of Drugs Regulations. In reality then Sainsbury’s is selling a product that is legally classified as a class B drug.
Cannabis Trades Association Receives Official Endorsement From the MHRA.
For nearly two years the Cannabis Trades Association (CTA) has been working with the Medicines and Healthcare products Regulatory Agency (MHRA), the Food Standards Agency (FSA), the Home Office, Trading Standards and other UK authorities to bring order and professional standards to the growing market in legal cannabis and CBD products.
The MHRA has now officially recognised CTA by inclusion in its Guidance Note 8 ‘A guide to what is a medicinal product’.
This is long overdue recognition for the CTA’s work which includes regular liaison with the authorities, providing guidance to businesses operating within the market on the law, regulations, professional and quality standards. The CTA with the MHRA and FSA is also in the process of developing the Cannabis Products Directive (CPD), a framework for regulation and licensing of all cannabis and cannabinoid products. CPD has been translated and submitted to all 28 member states of the EU by the European Food Safety Agency (EFSA). It is anticipated that CPD will become UK law within the next two years and will relieve the Home Office of the burden of the cannabis regulation and licensing process, placing it in expert hands.
The CTA was initially conceived at a meeting in Manchester Airport in September 2016. In November 2016, with the assistance of Crispin Blunt MP, then a member of the CLEAR Advisory Board, it was invited to an initial meeting with the MHRA to represent the emerging CBD industry. The market for legal, low-THC cannabis products derived from industrial hemp had grown rapidly within just a few months but was becoming out of control with a multitude of new companies making unlawful medical claims for their products, which themselves were totally unregulated and of inconsistent quality and unknown provenance.
Through negotiation and a growing relationship with the authorities, CTA was instrumental in bringing the market back from the brink of a serious clampdown. Now, with over 300 full members and more than 1200 registered sellers, CTA encompasses not just CBD suppliers but also licensed growers and producers of cannabis and businesses involved in the long term development of cannabis products.
CTA is closely involved in the rapidly developing reform of the laws around medical use of cannabis and will be working with the authorities to manage development of the products and systems required for what is expected to be a huge new market.
WARNING. CBD Flowers, Buds, Weed, Hash Are NOT Legal In The UK.
This is an extremely serious warning which people need to take seriously. Both CLEAR and the Cannabis Trades Association have independently dealt with several people who are being prosecuted for possession. The law treats these products exactly the same as any other cannabis. It makes no difference what the THC level is, it is a class B drug and the penalty for possession is up to five years in jail and an unlimited fine.
The confusion arises because of the misunderstood idea that the legal limit for THC is a maximum of 0.2%. This is the limit for a low THC cultivation licence for what is defined as industrial hemp – but you still need a licence! Without the licence the law regards industrial hemp exactly the same as the highest THC cannabis that the tabloids would describe as ‘super strength skunk’.
Products ‘derived from’ industrial hemp such as CBD oil or hemp teas can be ‘exempt products’ but there is yet more confusion here. The THC limit in these products is not 0.2% because, self-evidently, when you extract oil from a low THC cannabis plant you concentrate the THC. The limit in these products is 1mg of THC per container. It doesn’t matter how large or small the container is, the limit is 1mg. That limit also applies to the other ‘controlled drug’ found in such products, cannabinol (CBN). ‘Exempt products’ must not contain more than 1mg of THC and/or 1mg of CBN in any single container. The law that defines this is the Misuse of Drugs Regulations 2001. 2.(1)(c).
There are a number of websites offering these products for sale and, notoriously, one particular shop in Portobello Road. Whilst these sellers may well misunderstand the law, ignorance is no defence. It is almost inevitable that sooner or later one or more of these sellers will be prosecuted and go to jail.
An email seeking confirmation of the position from the Home Office was replied to as follows:
“Thank you for your email.
I can confirm that the leaves and flowers of the genus Cannabis are controlled and defined as cannabis as outlined in Section 37(1) of the Misuse of Drugs Act 1971
“cannabis” (except in the expression “cannabis resin”) means any plant of the genus cannabis or any part of any such plant (by whatever name designated) except that it does not include cannabis resin or any of the following products after separation from the rest of the plant, namely—
(a)mature stalk of any such plant,
(b)fibre produced from mature stalk of any such plant, and
(c)seed of any such plant;”.
Once the separation of the stalk and seeds from the plant has occurred it will not be defined as cannabis. This also extends to the fibre produced from the stalk.
Regards
Jill Frankham
Senior Compliance Officer
Drugs & Firearms Licensing Unit”
Let’s Nail the Home Office’s Latest Smokescreen About Medical Cannabis
As the evidence and support for legal access to cannabis for medical use grows, so the Home Office adjusts and reframes its arguments in denial.
This should come as no surprise. The ‘hostile environment’ revealed by the Windrush scandal runs through the Home Office like a stick of rock. The culture of this department is defined by Theresa May and it reflects her character and personality. It is secretive, demands total control and micro management of everything it touches and whenever it is challenged it finds another excuse to maintain its iron rule. It is institutionally dishonest.
A Home Office spokeswoman said:
“We recognise that people with chronic pain and debilitating illnesses are looking to alleviate their symptoms. However, it is important that medicines are thoroughly tested to ensure they meet rigorous standards before being placed on the market, so doctors and patients are assured of their efficacy and safety.”
The truth is rather different. In every jurisdiction throughout the world where medicinal cannabis has been legally regulated, it is through a special system outside pharmaceutical medicines regulation. You cannot regulate a 500 molecule plant-based medicine in the same way as a single molecule synthesised in a lab.
Regulation by the MHRA is the final excuse, the last obstacle to a revolution in healthcare in the UK. We need an ‘Office of Medicinal Cannabis’ as there is in the Netherlands, or ‘Access to Cannabis for Medical Purposes Regulations’ as administered by Health Canada. Colorado has its ‘Medical Marijuana Registry Program’ and other US states have similar arrangements. Israel’s Ministry of Health has its ‘Medical Cannabis Unit’. In Australia, its equivalent of the MHRA, the Therapeutic Goods Administration, has established its own set of medical cannabis regulations.
Every other government that has recognised the enormous benefit that medicinal cannabis offers has come to the same conclusion: cannabis is a special case. It is far more complex but much, much safer than pharmaceutical products.
So next time you hear this, the last, lame excuse from a government ideologically opposed to this long overdue reform, treat it and them with the contempt they deserve. They prefer that people should continue in pain, suffering and disability than that they should do what science and medicine says is right.
Peter Reynolds 
Source: https://s3.eu-west-2.amazonaws.com/assets.clear-uk.org/taxukcan.pdf
The £900 million figure being touted around by the Taxpayers’ Alliance as the savings that could be achieved from legalising cannabis is a massive underestimate and isn’t based on the sort of model that is currently being implemented in US states.
CLEAR commissioned independent research in 2011 which shows that a model in the UK simlar to that in Colorado would produce a net gain to the UK economy of around £6.7 billion pa and perhaps as high as £9.5 billion pa.
Ben Ramanauskas, who authored the Taxpayers’ Alliance report, has referenced the research we commissioned in his study but has only considered the savings and not the massive opportunities for additional tax revenue which arise from bringing a £6 billion market out of the black economy.
Full study available here: https://s3.eu-west-2.amazonaws.com/assets.clear-uk.org/taxukcan.pdf